Table 3.
Full Sample | Free From CVD/Cancer at Baseline and Removing Early Follow‐Up | Never‐Smokers, Free From CVD/Cancer at Baseline and Removing Early Follow‐Up | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Women (n=40 737, 665 Deaths) | Men (n=36 432, 1066 Deaths) | Women (n=35 080, 385 Deaths) | Men (n=31 863, 621 Deaths) | Women (n=22 036, 186 Deaths) | Men (n=16 848, 237 Deaths) | |||||||
Multivariable‐Adjusted Including BF% | Multivariable‐Adjusted Including BF% | Multivariable‐Adjusted Including BF% | ||||||||||
W/kg body weight | ||||||||||||
Least fit quintile | Reference | Reference | Reference | Reference | Reference | Reference | ||||||
2 | 0.85 (0.68–1.07) | 0.82 (0.69–0.97) | 0.86 (0.63–1.16) | 0.77 (0.61–0.96) | 0.95 (0.61–1.48) | 0.66 (0.45–0.97) | ||||||
3 | 0.86 (0.68–1.08) | 0.75 (0.62–0.89) | 0.84 (0.61–1.15) | 0.71 (0.56–0.90) | 0.98 (0.62–1.56) | 0.77 (0.53–1.12) | ||||||
4 | 0.71 (0.55–0.91) | 0.69 (0.57–0.83) | 0.75 (0.54–1.05) | 0.66 (0.52–0.85) | 1.08 (0.67–1.72) | 0.70 (0.47–1.04) | ||||||
Most fit quintile | 0.83 (0.65–1.06) | 0.65 (0.53–0.80) | 1.14 (0.83–1.56) | 0.60 (0.46–0.79) | 1.44 (0.91–2.27) | 0.56 (0.36–0.86) | ||||||
W/kg FFM | ||||||||||||
Least fit quintile | Reference | Reference | Reference | Reference | Reference | Reference | ||||||
2 | 0.90 (0.72–1.13) | 0.82 (0.69–0.97) | 0.98 (0.72–1.33) | 0.73 (0.59–0.92) | 0.97 (0.61–1.53) | 0.71 (0.49–1.04) | ||||||
3 | 0.76 (0.60–0.97) | 0.78 (0.65–0.94) | 0.74 (0.53–1.03) | 0.77 (0.61–0.97) | 1.04 (0.66–1.64) | 0.75 (0.51–1.09) | ||||||
4 | 0.85 (0.67–1.08) | 0.68 (0.56–0.82) | 0.97 (0.71–1.33) | 0.63 (0.49–0.82) | 1.15 (0.73–1.82) | 0.79 (0.53–1.16) | ||||||
Most fit quintile | 0.79 (0.62–1.01) | 0.67 (0.55–0.82) | 1.02 (0.75–1.40) | 0.63 (0.48–0.81) | 1.29 (0.82–2.04) | 0.65 (0.42–0.99) |
Multivariable‐Adjusted Including CRF/FFM | Multivariable‐Adjusted Including CRF/FFM | Multivariable‐Adjusted Including CRF/FFM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
BMI status | ||||||||||||
Normal weight | Reference | Reference | Reference | Reference | Reference | Reference | ||||||
Overweight | 1.02 (0.85–1.22) | 0.99 (0.85–1.16) | 0.99 (0.78–1.26) | 1.02 (0.83–1.25) | 1.00 (0.71, 1.41) | 1.25 (0.91, 1.72) | ||||||
Obese | 1.19 (0.96–1.47) | 1.11 (0.93–1.33) | 1.23 (0.93–1.62) | 1.10 (0.86–1.39) | 1.30 (0.88, 1.93) | 1.14 (0.77, 1.70) | ||||||
BF% status* | ||||||||||||
Low BF | Reference | Reference | Reference | Reference | ||||||||
Medium BF | 0.99 (0.78–1.25) | 0.97 (0.78–1.19) | 0.91 (0.64, 1.30) | 1.04 (0.75, 1.43) | ||||||||
High BF | 1.14 (0.86–1.50) | 1.01 (0.80–1.29) | 1.32 (0.90, 1.94) | 0.89 (0.60, 1.33) |
Hazard ratios with 95% CI. Multivariable‐adjusted: age (time scale), sex, Townsend index, education, partner status, ethnicity, employment status, diet pattern, alcohol intake, smoking status, television viewing, depression, asthma, hormone replacement therapy (women only), β‐blockers, calcium channel blockers, statins, hypertension, and diabetes mellitus (analysis in full sample additionally adjusted for prevalent cardiovascular disease [CVD] and cancer). BMI indicates body mass index; CRF, cardiorespiratory fitness; FFM, fat‐free mass; and W/kg, watts per kilogram.
Body fat percentage (BF%) status was defined based on distribution among CVD and cancer‐free participants at baseline, so was not analyzed in the full sample.